ALLO Similar Chart Price Prediction
The price of ALLO is predicted to go up -16.67%, based on the high correlation periods with HROW. The similarity of these two price pattern on the periods is 96.16%.
ALLO
HROW
Down: -16.67%Similarity: 96.16%
ALLO Revenue Forecast
ALLO EPS Forecast
ALLO FAQs
What is bull’s view on ALLO?
What is bear's view on ALLO?
What is ALLO revenue forecast for next quarter？
What is ALLO eps forecast for next quarter？
ALLO Analyst's Forecast
Biren Amin
Piper Sandler
Buy
2024-11-14
Price Target
$11 → $9
Upside
+257.85%
Piper Sandler analyst Biren Amin lowered the firm's price target on Allogene Therapeutics to $9 from $11 and keeps an Overweight rating on the shares. The firm notes Allogene announced the discontinuation of enrollment in the phase 1 cohort of ALPHA2 due to a slower than expected enrollment rate. The program had enrollment challenges as evident by moving timelines by a quarter when announced in Q2 earnings in August due to prioritization of the ALPHA3 trial. Piper had expected for cemacel to have a good probability of success, if not better than Breyanzi, due to its allogeneic approach which would address issues with auto CAR T in CLL, i.e. CLL patients' cells are more exhausted.
